| Summary: | <p>Abstract</p> <p>Background</p> <p>Zic zinc finger proteins are present in the developing rodent meninges and are required for cell proliferation and differentiation of meningeal progenitors. Although human <it>ZIC </it>genes are known to be molecular markers for medulloblastomas, their expression in meningioma has not been addressed to date.</p> <p>Methods</p> <p>We examined the mRNA and protein expression of human <it>ZIC1</it>, <it>ZIC2</it>, <it>ZIC3</it>, <it>ZIC4 </it>and <it>ZIC5 </it>genes in meningiomas in comparison to other brain tumors, using RT-PCR, analysis of published microarray data, and immunostaining.</p> <p>Results</p> <p><it>ZIC1</it>, <it>ZIC2 </it>and <it>ZIC5 </it>transcript levels in meningiomas were higher than those in whole brain or normal dura mater, whereas all five <it>ZIC </it>genes were abundantly expressed in medulloblastomas. The expression level of <it>ZIC1 </it>in public microarray data was greater in meningiomas classified as World Health Organization Grade II (atypical) than those classified as Grade I (benign). Immunoscreening using anti-ZIC antibodies revealed that 23 out of 23 meningioma cases were ZIC1/2/3/5-immunopositive. By comparison, nuclear staining by the anti-ZIC4 antibody was not observed in any meningioma case, but was strongly detected in all four medulloblastomas. ZIC-positive meningiomas included meningothelial, fibrous, transitional, and psammomatous histological subtypes. In normal meninges, ZIC-like immunoreactivities were detected in vimentin-expressing arachnoid cells both in human and mouse.</p> <p>Conclusions</p> <p>ZIC1, ZIC2, and ZIC5 are novel molecular markers for meningiomas whereas <it>ZIC4 </it>expression is highly selective for medulloblastomas. The pattern of <it>ZIC </it>expression in both of these tumor types may reflect the properties of the tissues from which the tumors are derived.</p>
|
|---|
